Skip to main content
Top

Convolutional neural networks for the differentiation between benign and malignant renal tumors with a multicenter international computed tomography dataset

Published in:

Abstract

Objectives

To use convolutional neural networks (CNNs) for the differentiation between benign and malignant renal tumors using contrast-enhanced CT images of a multi-institutional, multi-vendor, and multicenter CT dataset.

Methods

A total of 264 histologically confirmed renal tumors were included, from US and Swedish centers. Images were augmented and divided randomly 70%:30% for algorithm training and testing. Three CNNs (InceptionV3, Inception-ResNetV2, VGG-16) were pretrained with transfer learning and fine-tuned with our dataset to distinguish between malignant and benign tumors. The ensemble consensus decision of the three networks was also recorded. Performance of each network was assessed with receiver operating characteristics (ROC) curves and their area under the curve (AUC-ROC). Saliency maps were created to demonstrate the attention of the highest performing CNN.

Results

Inception-ResNetV2 achieved the highest AUC of 0.918 (95% CI 0.873–0.963), whereas VGG-16 achieved an AUC of 0.813 (95% CI 0.752–0.874). InceptionV3 and ensemble achieved the same performance with an AUC of 0.894 (95% CI 0.844–0.943). Saliency maps indicated that Inception-ResNetV2 decisions are based on the characteristics of the tumor while in most tumors considering the characteristics of the interface between the tumor and the surrounding renal parenchyma.

Conclusion

Deep learning based on a diverse multicenter international dataset can enable accurate differentiation between benign and malignant renal tumors.

Critical relevance statement

Convolutional neural networks trained on a diverse CT dataset can accurately differentiate between benign and malignant renal tumors.

Key points

• Differentiation between benign and malignant tumors based on CT is extremely challenging.
• Inception-ResNetV2 trained on a diverse dataset achieved excellent differentiation between tumor types.
• Deep learning can be used to distinguish between benign and malignant renal tumors.

Graphical Abstract

Title
Convolutional neural networks for the differentiation between benign and malignant renal tumors with a multicenter international computed tomography dataset
Authors
Michail E. Klontzas
Georgios Kalarakis
Emmanouil Koltsakis
Thomas Papathomas
Apostolos H. Karantanas
Antonios Tzortzakakis
Publication date
01-12-2024
Publisher
Springer Vienna
Published in
Insights into Imaging / Issue 1/2024
Electronic ISSN: 1869-4101
DOI
https://doi.org/10.1186/s13244-023-01601-8
This content is only visible if you are logged in and have the appropriate permissions.
This content is only visible if you are logged in and have the appropriate permissions.

How can your team use biomarkers to improve management of AD? (Link opens in a new window)

0.5 AMA PRA Category 1 Credit(s)

Our experts explore using biomarker tests and interpreting results, establishing a shared decision-making approach with patients and caregivers, and applying biomarker testing to guide treatment strategies.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Learn more

How can you integrate PET into your practice? (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)™

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Learn more
Image Credits
Alzheimer’s disease in the biomarker era: preparing the multidisciplinary care team/© Springer Healthcare IME, Navigating neuroimaging in Alzheimer’s care: Practical applications and strategies for integration/© Springer Health+ IME